JAZZ
Jazz Pharmaceuticals Plc
NASDAQ · Healthcare · Biotechnology · IE
$232.12
+1.04%Year over year
Reported trailing growth
- Revenue
- +13.5%
- EBITDA
- +354.1%
- EBIT
- +293.9%
- EPS
- +160.1%
- Free cash flow
- +17.7%
- Operating cash flow
- +21.6%
Forward estimates
Based on analyst estimates
- Revenue
- +5.5%
- EBITDA
- +148.2%
- EPS
- +635.7%
Three-year CAGR
- Revenue
- +5.3%
- EBITDA
- -43.7%
- EBIT
- -37.7%
- Net income
- —
- EPS
- —
- Free cash flow
- +14.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026